Follicular Lymphoma Treatment Market Trends, Analysis, Size, Share, Growth, Forecast, 2024-2033 | Outlook, Mergers and Acquisitions, Competitive Landscape

The follicular lymphoma treatment market size has grown strongly in recent years. It will grow from $2.83 billion in 2023 to $3.09 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increased incidence of follicular lymphoma, advancements in cancer diagnostics, expanding aging population, clinical research and drug development, collaborations in oncology research.

The follicular lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to personalized medicine approaches, immunotherapy advancements, expanded access to innovative therapies, focus on quality of life, global oncology collaboration initiatives. Major trends in the forecast period include clinical trials and research initiatives, exploration of epigenetic modifiers, enhancements in radioimmunotherapy, application of artificial intelligence (ai), global collaboration for access to therapies.

Market Overview -
Follicular lymphoma treatment refers to the medical interventions and therapies aimed at managing and combating the progression of follicular lymphoma, a type of non-Hodgkin lymphoma characterized by abnormal cell growth in the lymphatic system. The medication is often administered into a vein (intravenously). Radiation therapy can be used to treat early-stage follicular lymphoma.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10758&type=smp

Follicular Lymphoma Treatment Market Surges Amidst Growing Prevalence
The rising prevalence of follicular lymphoma is expected to propel the growth of the follicular lymphoma treatment market moving forward. The prevalence of follicular lymphoma refers to the total number or proportion of individuals within a specific population diagnosed with follicular lymphoma at a given time or over a particular period. This shift has resulted from the rise in the aging population, genetic predisposition, improved diagnostic techniques, and increased awareness and screening. Follicular lymphoma treatment helps reduce the prevalence of follicular lymphoma by addressing the disease at various stages and aids in disease treatment and progression. The rise in the incidence of follicular lymphoma is boosting the growth of the follicular lymphoma treatment market. For instance, in January 2023, according to the American Cancer Society, a US-based Voluntary organization, non-Hodgkin lymphoma, a type of indolent follicular lymphoma, is the most frequent cancer in the US, accounting for around 4% of all cancers. The American Cancer Society projects that NHL will be diagnosed in approximately 80,550 persons (44,880 men and 35,670 women). This includes both adults and children. Therefore, the rising prevalence of follicular lymphoma is driving the growth of the follicular lymphoma treatment market.

Competitive Landscape -
Major companies operating in the follicular lymphoma treatment market report are AbbVie Inc.,Celgene Corporation,Bayer AG,Bristol Myers Squibb Company,F. Hoffmann-La Roche Ltd.,Johnson and Johnson Services Inc.,GlaxoSmithKline plc,Novartis AG,Merck & Co. Inc.,EpiZyme Inc.,Boehringer Ingelheim GmbH,CTI BioPharma Corp.,Spectrum Pharmaceuticals Inc.,Seattle Genetics Inc.,Applied Molecular Genetics Inc.,Daiichi Sankyo Company Ltd.,Pfizer Inc.,Incyte Corporation,MorphoSys AG,Regeneron Pharmaceuticals Inc.,Eli Lilly and Company,Seagen Inc.,Takeda Pharmaceutical Company,Abbott Laboratories, Nordic Nanovector ASA,ADC Therapeutics SA,MEI Pharma Inc.,BeiGene Inc.,TG Therapeutics Inc.,Amgen Inc.,Dr. Reddy's Laboratories Ltd.

Technological Advances Propel Follicular Lymphoma Treatment Market Forward
Technological advancements in the diagnosis and treatment of follicular lymphoma are a key trend-gaining opportunity in the follicular lymphoma treatment market. Companies operating in the follicular lymphoma treatment market are adopting advanced diagnoses and treatments for follicular lymphoma to sustain their position in the market. For instance, in December 2022, Genentech Inc., a US-based biotechnology company, received FDA approval for Lunsumio, a novel bispecific antibody for treating relapsed or refractory follicular lymphoma. This antibody is a new class of fixed-duration cancer treatment immunotherapy, and it is a readily available and off-the-shelf treatment options patients are not needed to wait to receive this immunotherapy treatment. The FDA approval is based on positive results from the Lunsumio Phase II GO29781 research in persons with extensively pretreated FL, particularly those at high risk of illness progression or unresponsive to prior treatments.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report

Key Segments -
The follicular lymphoma treatment market covered in this report is segmented -
1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents, Nucleoside Analogues, Anthracycline Derivatives, Other Treatments
2) By Product Type: Tablets, Capsules, Injectables, Other Product Types
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.